Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

What to Expect From Revvity's Next Quarterly Earnings Report

April 12, 2026 at 11:49 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $10 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. The leading research and diagnostic firm is expected to announce its fiscal first-quarter earnings for 2026 in the near term.

Ahead of the event, analysts expect RVTY to report a profit of $1.02 per share on a diluted basis, up 1% from $1.01 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

For the full year, analysts expect RVTY to report EPS of $5.40, up 6.7% from $5.06 in fiscal 2025. Its EPS is expected to rise 11.1% year over year to $6 in fiscal 2027.

RVTY stock has underperformed the S&P 500 Index’s ($SPX) 29.4% gains over the past 52 weeks, with shares down 3.5% during this period. Similarly, it underperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 9.2% gains over the same time frame.

Revvity's underperformance stemmed from the Trump administration's new global tariffs, sparking fears of trade disruptions and cost hikes for companies with international operations.

Analysts’ consensus opinion on RVTY stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 18 analysts covering the stock, eight advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and nine give a “Hold.” RVTY’s average analyst price target is $118.13, indicating a potential upside of 31.6% from the current levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article